Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 at Citizens Jmp

Protagonist Therapeutics (NASDAQ:PTGX) had its target price increased by investment analysts at Citizens Jmp from $102.00 to $112.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective indicates a potential upside of 26.81% from the stock’s previous close.

Several other equities analysts have also recently weighed in on PTGX. JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Jefferies Financial Group raised their price objective on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Barclays upped their price target on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. HC Wainwright boosted their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Weiss Ratings downgraded shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $98.83.

Protagonist Therapeutics Stock Performance

PTGX traded up $1.22 during trading on Thursday, reaching $88.32. 26,657 shares of the company’s stock were exchanged, compared to its average volume of 717,310. The firm has a market capitalization of $5.52 billion, a PE ratio of 142.39 and a beta of 2.26. The company’s fifty day moving average price is $84.07 and its 200-day moving average price is $76.51. Protagonist Therapeutics has a fifty-two week low of $35.95 and a fifty-two week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The business had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts forecast that Protagonist Therapeutics will post 2.43 earnings per share for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other news, Director Lewis T. Williams sold 18,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the completion of the sale, the director directly owned 7,825 shares in the company, valued at $644,936.50. This represents a 69.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total value of $410,000.00. Following the completion of the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,897,430. This trade represents a 5.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 203,167 shares of company stock worth $16,889,199. 4.90% of the stock is currently owned by insiders.

Institutional Trading of Protagonist Therapeutics

Several large investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its stake in Protagonist Therapeutics by 11.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after purchasing an additional 146 shares in the last quarter. Farther Finance Advisors LLC grew its position in Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Protagonist Therapeutics by 1.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after acquiring an additional 193 shares during the last quarter. Maryland State Retirement & Pension System increased its position in shares of Protagonist Therapeutics by 2.3% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock valued at $751,000 after purchasing an additional 196 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Protagonist Therapeutics by 8.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock worth $258,000 after acquiring an additional 221 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.